71 results
8-K
EX-99.1
KPRX
Kiora Pharmaceuticals Inc
25 Mar 24
Results of Operations and Financial Condition
7:03am
-effective paths to market,” added Melissa Tosca, EVP Finance. “For 2024, we expect to increase our R&D spend, with expenses for KIO-301 offset by quarterly … of patients in Phase 2 clinical trials, with trial-related expenses for KIO-301 offset by reimbursement from TOI.
General and administrative expenses
8-K
EX-99.1
KPRX
Kiora Pharmaceuticals Inc
8 Aug 23
Kiora Pharmaceuticals Announces Q2 2023 Earnings and Business Update, Highlighting Pipeline Updates and Clinical Development Progress
7:14am
personnel and facilities expenses offset by an increased investment in clinical trial activities to support the advancement of KIO-301.
Kiora ended
424B1
wh9b18by1iu3uvan
2 Jun 23
Prospectus with pricing info
5:08pm
424B3
disyprjexc ga33l
28 Dec 22
Prospectus supplement
4:48pm
424B1
asc42w
22 Jul 22
Prospectus with pricing info
6:00pm